site stats

First study niraparib

WebMar 1, 2024 · The NDA is supported by data from the MAGNITUDE study (NCT03748641), a Phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of niraparib plus AAP as a first-line treatment in patients with mCRPC, with or without alterations in HRR associated genes. 1 Patients with HRR gene … WebApr 11, 2024 · At the beginning of the study period, due to economic reasons, niraparib was often reserved as a last resort when patients were resistant or intolerable to …

Janssen Submits New Drug Application to the U.S. Food and Drug ...

WebJan 1, 2024 · This study f … The JASPER clinical trial studied a new combination treatment for advanced or metastatic non-small cell lung cancer (NSCLC). ... ≥50% (cohort 1) or 1%-49% (cohort 2) received first-line niraparib (200 mg once daily) plus pembrolizumab (200 mg every 3 weeks). The primary end point was investigator-assessed objective response ... WebJul 7, 2024 · Despite a very small sample size, it is notable that the median progression-free survival in niraparib plus nivolumab was similar to the placebo group of the POLO study (3·8 months), whereas the median progression-free survival of 10·4 months in the niraparib plus ipilimumab group was closer to that shown in the experimental group of the POLO ... hyllden heights hildenborough https://noagendaphotography.com

Real-worldoutcomesofniraparibtreatmentinpatients …

WebFeb 1, 2024 · Niraparib late-breaking data: · First results from the Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone as a first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations (Abstract #12) … WebThe recommended niraparib dose for first-line maintenance treatment of advanced ovarian cancer is based on body weight or platelet count. For patients weighing less than 77 kg … WebApr 12, 2024 · The investigational PARP inhibitor senaparib (JS109/IMP4297) was found to prolong progression-free survival (PFS) in patients with advanced ovarian cancer, meeting the primary end point of the phase 3 FLAMES study (NCT04169997). 1. Senaparib was designed to selectively bind to PARP 1/2 and prevent PARP-mediated repair of single … hyl lc tablet

Time to First Subsequent Therapy (TFST) and

Category:Phase 3 Trial Further Examines Maintenance Mirvetuximab …

Tags:First study niraparib

First study niraparib

PRIMA study: Niraparib maintenance improves PFS in advanced OC

WebSep 23, 2024 · The FDA approved niraparib for patients with HRD-positive advanced ovarian cancer in October 2024 based on data from the single-arm QUADRA Study (NCT02354586) evaluating the agent vs placebo. 1 ... WebFeb 16, 2024 · Chi et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. ASCO GU 2024.

First study niraparib

Did you know?

WebFeb 14, 2024 · 1 Chi et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant ... WebMar 21, 2024 · The PRIMA study previously conducted by Zai Lab’s partner GlaxoSmithKline plc (GSK) demonstrated that niraparib conferred a PFS benefit to …

WebApr 29, 2024 · On April 29, 2024, niraparib was approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal … WebFeb 14, 2024 · SAN FRANCISCO, Feb. 14, 2024 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the Phase 3 …

WebMar 22, 2024 · Dr Li noted that niraparib is approved as first-line maintenance in ovarian cancer based on results of the PRIMA study (ClinicalTrials.gov Identifier: NCT02655016 … WebMar 23, 2024 · The phase III MAGNITUDE study was designed to compare the efficacy and safety of niraparib + AAP versus placebo + AAP for first-line mCRPC. Clinical data have shown the efficacy of combining androgen receptor–targeted therapy and a PARP inhibitor in metastatic prostate cancer, but the patient population who could have an optimal …

WebNov 30, 2024 · A study of niraparib combined with MGD013 in patients with advanced or metastatic solid tumor who failed prior treatment. clinicaltrials.gov. Updated April 1, 2024. Accessed November 30, 2024 ...

WebOct 29, 2024 · European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer . For media and investors only. ... hyllie boulevard 9c malmöWebApr 11, 2024 · The phase III PRIMA study randomized 733 patients with stage III/IV ovarian cancer who responded to first-line platinum-based chemotherapy in a 2:1 ratio to receive maintenance niraparib (n = 487) or placebo (n = 246). 1,2 Patients were randomized within 12 weeks of finishing the last cycle of chemotherapy. The study met the primary … hyll bandWebMar 22, 2024 · The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the Society of Gynecologic Oncology (SGO) 2024 Virtual … hyllis bookshelf